 Shares of Onconova Therapeutics NASDAQ:ONTX decreased 1.89 in after-market trading after the company reported Q2 results.Quarterly Results Earnings per share rose 93.33 over the past year to 0.04, which missed the estimate of 0.03.Revenue of 56,000 declined by 97.23 year over year, which missed the estimate of 170,000.Looking Ahead Earnings guidance hasnt been issued by the company for now.Onconova Therapeutics hasnt issued any revenue guidance for the time being.Details Of The Call Date: Aug 12, 2020View more earnings on ONTXTime: 04:30 PMET Webcast URL: Stock Performance 52-week high: 2.8452-week low: 0.10Price action over last quarter: Up 202.02Company Description Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks signaling by targeting RAS effeccellular tor pathways.See more from Benzinga Earnings Scheduled For August 12, 2020C 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 